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•	 Bacteriophage can be used as an antimicrobial agent for treatment of bacterial infection.
•	 Bacterial resistance to routine antibiotics is a big challenge in the world.
•	 Specificity	toward	bacteria	is	one	of	the	important	characteristic	of	phages.
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ABSTRACT
Despite the progress in treatment of infectious diseases, ability of microorganisms to 
develop the resistance to routine antibiotics has still remained as a big global challenge in 
clinics. This subject matter keeps the infections top in the list of life threatening diseases 
especially in those individuals suffering from nosocomial infections. The importance of 
this	global	health	challenge	urges	researchers	 to	find	an	alternative	solution	with	more	
efficacies	to	treat	infections.	There	are	some	alternative	approaches	by	which	the	global	
spread of resistant bacteria could be controlled. Through these ways, using bacteriophages 
instead of different generation of antibiotics brings many promises. According to results of 
different studies using bacteriophages in the management of infectious disease especially 
in nosocomial infections not only helps to reduce the spread of antibiotics resistance but 
also raises the hopes for the rescue of the suffering patients. Bacteriophages can open a 
new therapeutic window in the control and the treatment of the infectious disease with 
better	efficacy.
Phage Therapy as a New Approach in Treating Emerging Antibiotic 
Resistant Infections
Review Article
Trends in Peptide and Protein Sciences
2017ˏVol. 2ˏ No. 1ˏ 15-23
Article history:
Received: 22 September 2017
Accepted: 18 November 2017 
Introduction 
Our knowledge about the mechanisms which microbes 
use to evade novel antibiotic agents and inactivating new 
antibiotics is crucial, as we are now facing substantial 
infectious-disease challenges (Havaei et al., 2010; 
Ghasemi et al., 2013). The history of antibiotics discovery 
and antibiotics resistance show this fact that while, we try 
to use high potent and newly board spectrum antibiotics 
to control infections, microbes evolve new strategies 
to evade. The emerging of resistant strains of bacteria 
is more threatening when exists among hospitalized 
patients. The current stage of nosocomial infections and 
their mortality rates indicate to this fact that there is an 
essential need for new approaches to combat emerging 
infections and the global spread of drug-resistant bacterial 
pathogens (Pourmand et al., 2012; Liapikou et al., 
2013).
 DOI: http://dx.doi.org/10.22037/tpps.v2i1.19662
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Bacteriophage therapy
Phage therapy including the therapeutic use of 
bacteriophages is considered as one of the new approaches 
for treating infection especially with resistant bacteria. 
Historically, application of bacteriophages returns to the 
ancient time when reports of river waters with ability 
to cure infectious diseases, such as leprosy, have been 
documented.	In	fact,	bacteriophages	are	bacterial	specific	
viruses	 that	 act	much	more	 specifically	 than	 antibiotics	
(Kingwell et al., 2015). 
Synthetic chemotherapeutics agent (salvarsin and 
sulpha	 drugs)	 were	 the	 first	 antibacterial	 compounds	
that were discovered by human. Surprisingly, phage 
therapy	was	the	second	option	before	antibiotics.	The	first	
antibiotic (penicillin) has been tested in 1930 after two 
decades	of	 the	first	 phage	 therapy	 in	1919	 (Wainwright	
et al., 1986). Discovery of antibiotics causes the phage 
therapy to be superseded for a long time, but nowadays 
by the presence of MDR (multi-drug resistant) bacteria, 
a need for new alternative or combination therapy urges 
scientists to reconsider phages and their potential for 
eradicating infectious bacteria (McCarville et al., 2016). 
The	 narrow	 spectrum	 and	 specificity	 allow	
bacteriophages to be chosen as harmless agents not only 
to the host organism (human, animal, or plant), but also 
to	 other	 beneficial	 bacteria	 such	 as	 gut	 flora	 (Chapot-
Chartier, 2014). In this regard, using bacteriophages 
for the treatment of infections can reduce the risk 
of opportunistic infections due to keeping the good 
bacteria. As bacteriophages only replicate in vivo, a 
much smaller dose is needed to have therapeutic effect, 
this is another advantage of phage therapy instead of 
antibiotic therapy. Bacteriophages also tend to be more 
successful	 than	 antibiotics	 especially	 in	 case	 of	 biofilm	
covered bacteria such as Pseudomonas aeruginosa or 
Staphylococcus aureus, to which antibiotics typically 
cannot penetrate to (Chhibber et al., 2013). Interest 
in bacteriophages has recently renewed worldwide, 
and the laboratory tests suggest that bacteriophage-
based	 therapy	 may	 be	 beneficial	 for	 the	 treatment	 of	
pulmonary	 infections	 in	 cystic	 fibrosis	 (CF)	 patients	
(Hraiech et al., 2015). Meanwhile, as antibiotic resistance 
has become a major health problem against very 
current and important pathogen like Staphylococcus or 
Mycobacterium, currently bacteriophages are considered 
as a good candidate to replace (or in combination with 
antibiotic therapy) antibiotics against methicillin-resistant 
Staphylococcus aureus (MRSA) (Kali et al., 2013; Jensen 
et al., 2015). Of note, the application of bacteriophages 
is not limited to infections, they can also serve as drug-
delivery platform to kill cancer cells (Bar et al., 2008). 
Generally, there are two strategies of phage therapy to 
eradicate unwanted bacteria, to use natural phages or 
engineered phages (synthetic-based).
Natural phage therapies
Recent phage therapy as a novel antimicrobial infection 
is focused on the use of lytic tailed phages. The lytic 
tailed phages are member of Caudovirales order, whose 
families are Myoviridae, Podoviridae, and Siphoviridae 
(Fig.	1)	(Wittebole	et	al.,	2014).
The Caudovirales are an order of viruses  known as 
tailed bacteriophages and used in natural phage therapy 
(non-recombinant). Caudovirales have double stranded 
DNA (dsDNA) genomes, and a tail appendage that is 
attached to the icosahedral head of phage with a connector 
protein (Ackermann et al., 2012).
One of the advantages of tailed bacteriophages is 
that they can be found easily everywhere that bacteria 
are living (in animal, plants, etc.) (Hatfull et al., 2011). 
When	 tailed	 phages	 infect	 bacteria,	 before	 lysing	 the	
bacteria membrane to release its progeny virions, it 
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exploits many cellular systems of bacteria for production 
of virions and killing bacterial host (Chevallereau et al., 
2016).	Specificity	toward	bacteria	is	one	of	the	important	
characteristics of phages. Some phages can infect a few 
strains through one species and some of them can infect 
many strains through different species; for example some 
polyvalent phages like Mu that can infect many species 
like Escherichia, Erwinia, Citrobacter, Enterobacter, and 
Shigella (Ross et al., 2016). Also polyvalent w812 phage 
can infect around 700 strains of Staphylococcus aureus 
and	lyses	them	(Pantůcek	et	al.,	1998).	This	characteristic	
of	phages	can	help	to	eradicate	just	the	specific	unwanted	
bacteria within many available bacteria through the body, 
which cannot be done by Antibiotics, especially broad-
spectrum ones. Many antibiotic treatment side effects like 
diarrhea is because of dysbiosis effect and overgrowth 
of MDR strain of microorganisms which are all because 
of	non-selective	effect	of	chemical	antibiotics	(Francino	
et	 al.,	 2016).	 So	 the	 specificity	 and	 accuracy	 of	 phages	
activity can help to maintain the eubiosis and health of 
gastrointestinal microenvironment (Sulakvelidze et al., 
2001; Sarker and Brüssow, 2016). Broader host range 
phages are selected in process of screening and isolation; 
it means that the phages are isolated from environment 
and then screened against the commonly occurring 
bacteria causing diseases for determining the host rang of 
phages. One of the limitations of phage therapy is narrow 
host range of some phages which can be solved by using a 
phage mixture (phage cocktail). This cocktail can trigger 
many different host and receptors to prevent resistant 
mutant bacteria (Yen et al., 2017).
Synthetic phage therapies
By innovation of DNA sequencing technology and 
advancement of genetic engineering methods, it became 
possible to engineer and design recombinant phages with 
appropriate	 and	 novel	 characteristics.	 For	 example	 to	
broaden the bacterial host ranges of phage, it is possible 
to hybrid tails of some related phages (Table 1). Also by 
recombinant technology some genetic properties can be 
added	to	phages,	for	example	by	addition	of	specific	gene	
sequence for expressing exopolysaccharide-degrading 
enzyme,	 necessary	 for	 targeting	 biofilm,	 it	 is	 possible	
to improve the diffusion of phages (Lu and Collins, 
2007; Lin et al., 2012). Also it is possible to engineer p 
genes to express some cell-penetrating peptides to help 
phages break the mammalian membrane (Staquicini 
et al., 2011; Rangel et al., 2012). One drawback with 
natural phage therapy is that natural phages kill bacteria 
through lysing and rupturing bacterial cell (Roach and 
Donovan, 2015). Subsequent to fast lysis, the endotoxin 
of	 bacteria	 will	 release	 and	 cause	 inflammation	 in	
surrounding environment. To overcome this problem 
some engineered phages are designed in a way that they 
are knocked out in cell lysing genes (endolysin); so they 
Table 1. Synthetic phages based on T7 phage and T3 phage.*
Synthetic phage Structure Characteristics
T7T3 (C-gp17) combination of T7 phage with 410 aa of the C-terminal	of	T3	tail	fiber it can form plaque on E. coli ECOR16
T7T3 (gp17) combination of T7 phage with whole T3 tail fiber it can form plaque on E. coli ECOR16
T3T7 (C-gp17) combination of T3 phage with the 405 aa of the	C-terminal	of		T7	tail	fiber
it can form plaque on E. coli	BW25113	and	
E. coli MG1655 (like T3T7(gp17))
T3T7 (gp17) combination of T3 phage with whole T7 tail fiber
it can form plaque on E. coli	BW25113	and	
E. coli MG1655 (like T3T7(C-gp17)
T713a (C-gp17)
combination of a synthetic T7 phages (with 
optimized codon) with C-terminal amino 
acids	of	the	phage	13a	tail	fiber
it can form plaque on E. coli efficiently	
(but	T7	and	T7WT	cannot)
T713a (gp17)
combination of a synthetic T7 phages (with 
optimized codon) with whole amino acids of 
the	phage	13a	tail	fiber
it can form plaque on E. coli	so	efficiently	
(but	T7	and	T7WT	cannot)
T3R (gp17) combination of synthetic T3 phage with the R	tail	fiber
it can infect E. coli BL21, Klebsiella sp. 390 
and Y. ptb IP2666
T7K11 (gp11-12-17) combination of T7 phage with K11 phage tail it can infect Klebsiella sp. 390 but not E. coli
K11T7 (gp11-12-17) combination of K11 with T7 phage tail it can infect E. coli, but not Klebsiella
* Based on information of reference (Ando et al., 2015).
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are bacteriostatic instead of being bactericidal and also, 
they are called temperate phages (Matsuda et al., 2005; 
Nemeth et al., 2015). Engineered bacteriostatic phages 
also may be used as an adjuvant in antibiotic therapy 
to deliver some genes helping in disruption of bacterial 
cell-to-cell	communication	in	biofilm	which	can	improve	
antibiotics penetration (Pei and Lamas-Samanamud, 2014) 
or to design some temperate phages that carry sensitizing 
cassette genes and deliver these sensitizing proteins into the 
bacteria and thus sensitize bacteria to antibiotics (Edgar et 
al.,	2012).	But	always	there	is	a	risk	of	benefit	of	prophage	
encoded genes for bacterial as a host (Cumby et al., 2012). 
Also nonlytic bacterial death can be induced by the use 
of phagemid (phages that contain a plasmid within the 
phage origin of replication) that carry genes of some toxin 
protein and some peptide with antibacterial properties 
(Krom et al., 2015) and also making some sequence-
specific	CRISPR	(Clustered	Regularly	 Interspaced	Short	
Palindromic Repeats) system in phagemids to sensitize 
bacterial population toward antibiotics and killing bacteria 
indirectly (Bikard et al., 2014; Citorik et al.,2014; Pires 
et al., 2016). Antibiotic-resistant genes can be eliminated 
by phagemid that carry CRISPR RNAs sequence and 
subsequently disrupt transferring resistant genes to other 
bacterial	 strain,	 and	 as	 bacteria	 have	 not	 efficient	 end-
repairing systems, double stranded break induced with 
CRISPR cannot be repaired and will cause bacterial death 
(Bikard et al., 2014; Cui and Bikard, 2016).
Phage therapy 
The use of bacteriophage as an antimicrobial therapy 
known as phage therapy, have been tested in acute and 
chronic infectious diseases. But mostly the focus of recent 
phage therapy has been done on acute infection of small 
vertebrate animal. In some studies, phage therapy reduces 
the amount of bacteria to a level that host immune system 
could	be	able	 to	fight	and	remove	the	bacterial	 infection	
(Smith and Huggins, 1982; Debarbieux et al., 2010; 
Alemayehu et al., 2012). Many phage therapy studies 
have been done in treatment of pulmonary infection 
with antibiotic resistant phenotype like in pneumonia 
cystic	 fibrosis	 patients	 (Will	 et	 al.,	 2005;	McVay	 et	 al.,	
2007; Chhibber and Kumari, 2008; Debarbieux et al., 
2010; Singla et al., 2015) and patient suffering from 
gastrointestinal infections (Sarker et al., 2016).
Phage therapy in chronic infection 
Chronic infections may be caused by persistent (years 
or even decades) uncured infection which will show 
resistance to current antibiotics therapy. Chronic infections 
that might be made up from a population of diverse 
bacterial	strains,	create	poly-microbial	biofilms	making	a	
strong barrier for penetration of antibacterial agents. Even 
though	 specific	 antibody	 against	 chronic	 bacterial	 strain	
antigens may be detectable in serum, this is not enough to 
eradicate infections (Malik et al., 2017).
In the study of Alemayehu et al. (2012) they used 
two bacteriophages (myovirus	 (ϕNH-4)	 and	 a	podovirus 
(ϕMR299-2)	 that	 can	 kill	 both	 mucoid	 (NH57388A)	
and non-mucoid (P. aeruginosa MR299) P. aeruginosa 
strain	when	 forming	 biofilm	on	 cystic	 fibrosis	 epithelial	
cell	 lines	(CFBE41o).	After	 transfection	of	 the	epithelial	
cell line with the phages, the titer of phages increased 
100 fold which demonstrates that phages are replicating 
in bacteria. Also this phage mix was tested on murine 
lung contaminated with P. aeruginosa which effectively 
reduces the number of bacteria 3-4 fold log unit in 6 h.
Gutiérrez	et	al.	demonstrated	that	the	24	h	biofilm	of	
S. aureus IPLA16-rifR and S. epidermidis LO5081 was 
exposed with phages phiIPLA-RODI and phiIPLA-C1C 
while this phage therapy caused 5 log reduction of bacteria 
concentration with lytic ability of phages and also caused 
reduction	of	2	log	bacteria	adherence	of	biofilms	Gutiérrez	
et al. (2015). In another study by D.R. Alves et al. (2014), 
six novel bacteriophages that can effectively kill P. 
aeruginosa PAO1, were clinically isolated by screening 
process. This phage cocktail was tested on two types 
of	 static	 and	 dynamic	 24	 h	 biofilm	models	 (which	 have	





occurred after 48 h contamination.
Phage therapy in acute infection
Phage therapy has been tested on many types of acute 
diseases but in this review it is point to some of the most 
common one.
Phage therapy of antibiotic resistance respiratory 
infections 
Phage therapy is a new approach of treatment of respiratory 
infection caused by bacteria, such as Burkholderia 
cepacia complex (BCC), Staphylococcus aureus, 
Haemophilus influenzae, Mycobacterium Tuberculosis 
(TB), P. aeruginosain,	 Cystic	 fibrosis	 (CF)	 patients,	
and	 also	 Ventilator-associated-pneumonia	 (VAP)	 occur	
by P. aeruginosa, S. aureus, Streptococcus pneumonia, 
H. influenza, Acinetobacter baumannii, Klebsiella sp., 
Enterobacter sp., and Serrati sp. (Semler et al., 2014; 
Bodier-Montagutelli et al., 2017; Trend et al., 2017).
Phage therapy of antibiotic resistance wounds
Treatment of chronic wound like burning and diabetic 
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wound is a big worldwide problem. Bacteria that form 
biofilms	 are	 current	 in	 wound	 infection	 and	 reduced	
metabolic	 activity	 in	 biofilm	 and	 biofilm	 barrier	 for	
penetration of antimicrobial agents (antibiotics and 
antiseptics) make the treatment problematic. Two bacteria 
are important in resistant wound infections; S. aureus and 
P. aeruginosa.
In	one	study	by	McVay	et	al.	(2007)	thermal	burned	
mice were infected with lethal Pseudomonas aeruginosa 
and then were treated with single dose administration of 
cocktail phage (consist of three different P. aeruginosa 
specific	phages)	in	three	different	routes	of	intramuscular	
(IM), subcutaneous (SC), or intraperitoneal (IP). The 
study showed that phage therapy increased survival rates 
to 22-87% (8% without treatment) and also the treatment 
result was route dependent; the best result (87% survival) 
was seen in IP route of administration. Pharmacokinetic 
study of phage therapy showed IP administration resulted 
in earlier detected and higher concentration of phages 
in	 the	 blood,	 spleen,	 and	 liver	 (McVay	 et	 al.,	 2007)	 in	
comparison to IM or SC routes. The better result of IP 
route (earlier delivery of phages, longer remaining in 
circulation, higher concentration, and earlier detection 
of phages in many host organs) of administration of 
phages has been shown in one other study too (Chhibber 
et al., 2008). In another study by Chhibber et al. (2013), 
BALB/c mice with diabetic food S. aureus infection were 
evaluated by administration of phage MR-10, linezolid 
antibiotic, and non-treated control groups. The results 
showed that the group treated with both phage MR-10 and 
linezolid showed the higher reduction of bacterial load in 
wound in comparison to other treatment groups.
Phage therapy of antibiotic resistance gastrointestinal 
infections
In a study by Yen et al. (2017), three-phage ICP cocktail 
(against V. cholerae) administered to two animal models 
of cholera pathogenesis (mice and rabbits). The ICP 
phage cocktail orally administered to infant rabbit and 
mice 24 h before Vibrio cholera infection as prophylaxis. 
This phage cocktail reduce the colonization of V. cholera 
in infant mice and prevent the onset of the symptom of 
cholera in infant mice and this cocktail was effective as a 
prophylaxis treatment.
Tanji et al. (2005) performed a study to evaluate a 
cocktail of three phages SP15, SP21, and SP22 which 
were selected from feces of animal and sewage. These 
three phages were tested against batch cultures of E. 
coli and they saw the reduction in turbidity of the cell 
culture. They suspend phage cocktail in CaCO3 buffer for 
oral administration to the mice that were infected with 
E. coli	 O157:H7	 cells	 2	 days	 before.	 For	 9	 days	 after	
treatment the feces of the mice were assessed for presence 
of phages and bacterial cells. More rapid reduction in 
bacterial number and higher concentration of phages in 
mice feces and gastrointestinal tract were seen in group 
which received daily and repeated oral administration of 
cocktail phages. However, after day 9 of test period, the 
concentration of bacteria in feces of mice divided into 
two groups: group 1, who were treated with phages and 
group 2, who were not treated after infection with bacteria 
(control group) were not much different.
Stanford et al. (2010) tested the effect of a polymer-
encapsulated phages (Ephage) that is a cocktail 
phage	 which	 consist	 four	 wV8,	 rV5,	 wV7,	 and	 wV11	
bacteriophages that target E. coli O157:H7.They knew 
that these bacteriophages that targeted E. coli O157:H7 are 
sensitive to low pH and they will lose their activity in 20 
min in acidic condition of gastric milieu. So, the Polymer 
encapsulated form of this cocktail phage whose recovery 
percent activity after exposure to low acidity situation was 
acceptable (13.6%) rather than non-encapsulated one were 
tested on 16 steers. 24 steers were infected with nalidixic 
acid-resistant E. coli	O157:H7	(10(11)	CFU)	on	day	0.	8	
steers out of 24 were kept as control group without any 
treatment. The other was treated with Ephage on days -1, 
3, 6, and 8, in two ways. Eight steers were treated with 
Ephage that was put into gelatin capsules (each capsule 
contain 10(10)	 PFU)	 and	 the	 other	 8	 steers	 received	 the	
Ephage that were top-dressed on their feed (10(11)	PFU	per	
steer). Shedding of bacteria were tested for 10 days by 
fecal and swap sample. Both treatment strategy activities 
were acceptable and it was a little more in gelatin capsule 
way (1.82 × 10 (9)	 PFU/g	 in	gelatin	 capsule	 and	1.13	×	
10(9) PFU/g	by	 food).	Surprisingly	phages	 treatment	 did	
not decrease the concentration of bacteria in fecal but it 
reduced the duration of shedding of bacteria for 14 days 
in both way of treatment in comparison to control group.
In one study by Bardina et al. (2012), a cocktail phage 
compromise	of	three	bacteriophages	(UAB_Phi20,	UAB_
Phi78,	 and	 UAB_Phi87)	 against	 Salmonella enterica 
serovar Enteritidis and Typhimurium in two animal models 
was tested. In mouse model, one dose of the cocktail was 
administered exactly at the same time of infecting mouse 
by Salmonella and booster doses in 6, 24, and 30 h after 
infection induction. Mouse survival was 50% after phage 
therapy.	 In	 White	 Leghorn	 chicken	 specific-pathogen-
free	(SPF)	model	the	best	result	(reduction	of	Salmonella	
concentration in cecum) was seen in one phage therapy 
exactly one day before bacterial infection and colonization 
of bacteria in intestinal and again in days after infection.
Phage therapy trial in human
The most information on human phage therapy comes 
from two Eastern Europe countries, in the Poland in 
Hirszfeld Institute of Immunology and Experimental 
Therapy	 in	Wrocław,	 the	 largest	 city	 of	 Poland	 and	 in	
Georgia especially in Eliava Institute of Bacteriophages, 
R. Ajideh et al. / TPPS 2017 2 (1) 15-23
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Microbiology	and	Virology.	The	Eliava	 Institute	mainly	
works on producing phage cocktail formulation and 
implementation (Gill et al., 2010). Georgia is the 
first	 country	 in	 the	 world	 that	 used	 bacteriophages	 in	
medical practice as a standard route for both treatment 
and prophylaxis. A number of medical product and also 
over the counter phage therapy formulation are available 
for many applications in self-remediation or physician 
administered in non-serious problem. Many clinical trials 
have been done in Georgia so far, but much incomplete 
and no more information is available from those. Hirszfeld 
Institute in Poland is the second important source of 
information on phage therapy. They mainly work on 
individual therapy with phages in patient who suffer 
from antibiotic resistance and many studies and papers re 
available with details (Kutter1 et al., 2010).
In this section some studies done on human have 
been pointed. In study by Bruttin and Brüssow (2010), 
the safety of bacteriophage on 15 healthy adults volunteer 
was assessed. Some volunteers received E. coli phage 
T4 with high dose (105	 PFU/ml),	 some	 received	 lower	
phage T4 dose (103	PFU/ml)	in	their	drinking	water,	and	
some volunteer just received placebo. In the group that 
received higher dose of phage T4, phages can be detected 
in their fecal after one day of exposure but this prevalence 
was half in volunteers who received lower dose phage. 
Oral administration of phages did not decrease the E. 
coli number in fecal sample of volunteers. No critical 
adverse	effect	was	recorded	in	this	study	(just	five	people	
complained about gastric problems like nausea, more 
peristalsis movement, and stomachache and also just one 
complained about sore throat but none of them required 
any treatment). This adverse effect was not related to 
phage	dose.	No	T4-specific	 antibodies	were	detected	 in	
serum and the serum transaminase level was in normal 
range after treatment (Kutter et al., 2010).
Rhoads et al. (2009) have done a phase I trial to test 
the	bacteriophages	for	wound	that	are	difficult	to	treat.	It	
was tested on 42 patients with chronic venous leg ulcers 
(VLUs)	but	just	32	of	them	continue	up	to	the	end	of	the	
trial. The duration of treatment was 12 weeks and they 
were divided into two groups; test group, that were treated 
with	 bacteriophage	 cocktail	 compromised	 of	 specific	
phages against Pseudomonas aeruginosa, Staphylococcus 
aureus, and E. coli and the control group, that were treated 
with normal saline washing of wound. The result of 24 
weeks	 follow	 up	 showed	 that	 there	 was	 no	 significant	
difference between the control and test group in terms of 
adverse effect, safety, and in rates of wound healing and 
also	the	efficacy	should	be	studied	in	phase	II  trial.
Wright	et	 al.	 (2009)	developed	a	double	blind	small	
Phase I/II clinical trial on 24 patients with chronic otitis 
related to antibiotic resistant Pseudomonas aeruginosa. 
The patients were divided into two groups of treatment 
with phage and received placebo. Twelve patients were 
administered 0.2 ml (105	 PFU/ml)	 of	 a	 cocktail	 of	 six	
bacteriophages (named as Biophage-PA) dissolved in 
10% glycerol in phosphate-buffer saline, in their infected 
ear by dropping the phages by a needle. All patients 
visited 3 times after medication on days 7, 21, and 42 and 
were assessed by ear swap sample for P. aeruginosa strain 
resistant to antibiotics. Neither local and systemic toxicity 
nor any other important side effects were reported. In 
contrast to control group, the count of P. aeruginosa in 
treated group was dramatically lower and the treatment 
was	safe	and	had	an	appropriate	efficacy.
Sarker et al. (2016) recently studied a T4-like 
coliphages and placebo in children (6–24 month old 
males) with acute bacterial diarrhea by oral administration 
for 4 days. No adverse effect and also no improvement in 
child diarrhea situation were not recorded. The scientists 
of this study claimed that the treatment failure was 
possibly because of low titer of E. coli in gut transit of 
children (as coliphages, or any bacteriophages, need high 
titer	of	bacteria	for	amplification	to	be	effective)	and	also	
coliphage was orally administered to children without 
any anti-acid for protection from low acidity situation of 
stomach.
Another	 trial	 has	 been	 done	 recently	 by	 Fish	 et	 al.	
(2016) on 6 human with diabetic toe infections (bone and 
soft tissue infection by Staphylococcus aureus including 
most methicillin- resistant Staphylococcus aureus 
(MRSA) strains) that did not show desirable response to 
current antibiotic treatment. In this study weekly wound 
care was done as soft tissue debridement and dropping 
single lytic phage Sb-1 with broad host range against S. 
aureus (that is commercially available in Tbilisi, Georgia 
by Eliava Biopreparation in 10 ml vial containing around 
107–108	PFU/	ml)	into	wound	cavity	and	then	wrapped	the	
wound for 48 h with gauze. This staph mono-phage topical 
treatment was successful in all patients. All patients’ 
wound healed in around 6 weeks of bacteriophage therapy 
and just one special case (extremely poor vascularity) 
needed more treatment up to 18 weeks for wound healing 
(Sarker et al., 2016).
Rose et al. (2014) worked on a cocktail phage consist 
of tree bacteriophages against Pseudomonas aeruginosa 
and Staphylococcus aureus	(named	BFC-1	bacteriophage	
cocktail), which contain 109 pfu/ml of each phage) 
colonized on burn wounds. This trial was done under the 
approval of Belgian Medical Ethical Committee. Nine 
patients with burn wound infection received this cocktail 
phage 10 times. Half of patients received required 
systemic antibiotic treatment and the other half received 
BFC-1	 as	 treatment	 (1	ml	BCF-1	per	 50	 cm2 of burned 
area). Bacterial load was not changed in biopsy result of 
wound after treatment (both groups, treated with phage 
and antibiotic). However, they claimed that may be this 
result was because of low bacterial load in wound before 
the treatment. Also, Rose et al. understood that this was 
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better to spray the phage cocktail into the wound and also 
suggested formulating phage cocktail as gel or as a wound 
part of dressing.
Conclusion
Although,	 despite	 of	 all	 above	 benefits	 of	 using	
bacteriophages for the treatment of bacterial infections, 
it	 should	 be	 noted	 here	 that	 the	 strain	 specificity	 may	
be counted as a disadvantage and limiting factor for 
this promising agents (Pérez Pulido et al., 2016). In fact 
a phage will only kill a bacterium in which there is a 
specific	ligand	for	attachment.	To	overcome	this	problem	
and to improve the chances of success, the mixtures of 
phages as “bacteriophage cocktail” is often applied. The 
Recombinant phages and non-replicating phages derived 
from the conventional phages by genetic manipulation 
also dragged attentions due to their much more host 
diversity (Yuan et al., 2013). Genetically manipulated 
phages especially those encode lysosomal enzymes can 
be used as an adjuvant along with antibiotics for the 
treatment of hard to cure infections (Qadir et al., 2015). 
Bacteriophages in the management of infectious disease 
especially in the category of nosocomial infections, not 
only help to reduce the spread of antibiotics resistance but 
also, raised the hopes for the rescue of suffering patients 
(Abedon et al., 2011).
This is also important that it is possible for bacteria 
to develop resistance against phages, but in comparison 
to antibiotic resistance, the phage resistance might be 
easier to overcome (Labrie et al., 2010). Although the 
natural hosts for bacteriophages are bacteria, the patients’ 
immune system in some cases can also mount an immune 
response to the phage and this may be considered as 
another drawback of phage therapy (Górski et al., 2012).
Taken together, regarding to the global spread of 
bacterial resistant strains like MRSA and the importance 
of limiting antibiotic administration against this type 
of bacteria, the application of phages can at least have 
benefits	 for	 reducing	 the	 multidrug	 resistant	 strain,	 but	
still more studies are needed to introduce this strategy as 
totally safe. Also for entering the clinics, the phages need 
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